Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.4K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.4K
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.1K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.1K
Bacterial Transformation01:33

Bacterial Transformation

60.2K
In 1928, bacteriologist Frederick Griffith worked on a vaccine for pneumonia, which is caused by Streptococcus pneumoniae bacteria. Griffith studied two pneumonia strains in mice: one pathogenic and one non-pathogenic. Only the pathogenic strain killed host mice.
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
60.2K
Metal-Ligand Bonds02:51

Metal-Ligand Bonds

24.5K
The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
24.5K
Qualitative Analysis03:46

Qualitative Analysis

24.9K
For solutions containing mixtures of different cations, the identity of each cation can be determined by qualitative analysis. This technique involves a series of selective precipitations with different chemical reagents, each reaction producing a characteristic precipitate for a specific group of cations. Metal ions within a group are further separated by varying the pH, heating the mixture to redissolve a precipitate, or adding other reagents to form complex ions.
For instance, group IV...
24.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Blood·2026
Same author

Transient imaging changes accompany 'spinal ICANS' following CAR T-cell therapy for large B-cell lymphoma in adults.

British journal of haematology·2025
Same author

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.

Blood·2025
Same author

Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843.

Transplantation and cellular therapy·2025
Same author

Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG).

Hematological oncology·2025
Same author

Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

HemaSphere·2024

Related Experiment Video

Updated: Feb 13, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

847

Treating relapsed follicular lymphoma.

Thomas Erblich1, Silvia Montoto2

  • 1a Department of Haemato-oncology , St Bartholomew's Hospital , London , UK.

Expert Review of Hematology
|March 16, 2018
PubMed
Summary

Advanced follicular lymphoma (FL) is often incurable, with most patients relapsing after initial treatment. Current therapies include rituximab, anti-CD20 antibodies, and stem cell transplants, with new treatments under investigation.

Keywords:
Anti-CD20 monoclonal antibodiesindolent B-cell lymphomasnovel agents relapsed follicular lymphomastem cell transplant

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.3K
Separation of Follicular Cells and Oocytes in Ovarian Follicles of Zebrafish
11:35

Separation of Follicular Cells and Oocytes in Ovarian Follicles of Zebrafish

Published on: April 18, 2021

8.5K

Related Experiment Videos

Last Updated: Feb 13, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

847
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.3K
Separation of Follicular Cells and Oocytes in Ovarian Follicles of Zebrafish
11:35

Separation of Follicular Cells and Oocytes in Ovarian Follicles of Zebrafish

Published on: April 18, 2021

8.5K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Advanced follicular lymphoma (FL) is a challenging hematologic malignancy with a high relapse rate.
  • Current conventional therapies offer limited long-term cures for advanced FL.
  • The advent of rituximab has significantly altered the treatment landscape for FL.

Purpose of the Study:

  • To review current therapeutic strategies for relapsed follicular lymphoma in the rituximab era.
  • To discuss decision-making processes for treatment selection in relapsed FL.
  • To highlight novel agents and approaches currently under investigation for FL.

Main Methods:

  • Review of existing literature on follicular lymphoma therapies.
  • Analysis of treatment outcomes with rituximab and related agents.
  • Examination of emerging targeted therapies and immunotherapies.

Main Results:

  • Rituximab, second-generation anti-CD20 antibodies, and stem cell transplantation remain effective for relapsed FL.
  • Maintenance therapy with anti-CD20 antibodies improves outcomes.
  • Numerous novel targeted agents and immunotherapies are in development.

Conclusions:

  • Follicular lymphoma management is evolving towards a chronic disease model.
  • Tailored treatment approaches considering patient preferences and quality of life are crucial.
  • The integration of novel therapies promises improved outcomes for relapsed FL patients.